A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis

Authors

Stephen Schleicher MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

8-2024

Volume

191

Issue

2

Published In/Presented At

https://doi.org/10.1093/bjd/ljae266.102

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine

Document Type

Article